argenx NV ADR (ARGX)vsExelixis Inc (EXEL)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
EXEL
Exelixis Inc
$42.79
+2.92%
HEALTHCARE · Cap: $11.15B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 83% more annual revenue ($4.24B vs $2.32B). EXEL leads profitability with a 33.7% profit margin vs 30.5%. ARGX appears more attractively valued with a PEG of 0.83. EXEL earns a higher WallStSmart Score of 72/100 (B).
ARGX
Buy63
out of 100
Grade: C+
EXEL
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+67.0%
Fair Value
$130.10
Current Price
$42.78
$87.31 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Every $100 of equity generates 36 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 39.4%
Earnings expanding 84.2% YoY
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : EXEL
The strongest argument for EXEL centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 33.7% and operating margin at 39.4%.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : EXEL
The primary concerns for EXEL are PEG Ratio.
Key Dynamics to Monitor
ARGX profiles as a growth stock while EXEL is a mature play — different risk/reward profiles.
EXEL carries more volatility with a beta of 0.41 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
EXEL scores higher overall (72/100 vs 63/100), backed by strong 33.7% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Exelixis Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?